We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Simeon Taylor

Simeon I. Taylor MD, PhD

Professor of Medicine, University of Maryland School of Medicine; Director, Mid-Atlantic Nutrition Obesity Research Center, Baltimore, Maryland

Dr. Simeon Taylor studied at Harvard University (B.A., M.D., and Ph.D.) and received his clinical training at Massachusetts General Hospital (Internal Medicine and Endocrinology).  In 1979, he moved to the National Institutes of Health where he was Chief of the Diabetes Branch, NIDDK (1989-2000).  At NIH, his research focused on mechanisms of insulin resistance, genetics of insulin resistant diabetes, and investigations of innovative therapies including metreleptin to treat lipoatrophic diabetes.  His contributions were recognized by the Outstanding Service Award of the U.S. Public Health Service and the Outstanding Scientific Achievement Award of the American Diabetes Association.  In 2000, he moved to the pharmaceutical industry.  In his role as Vice President of Cardiovascular and Metabolic Disease Research at Bristol-Myers Squibb, he made contributions to R&D leading to four approved drugs: saxagliptin, dapagliflozin, metreleptin, and apixaban.  In 2013, he returned to academia where is currently Professor of Medicine in the Division of Endocrinology, Diabetes, and Nutrition at the University of Maryland School of Medicine. He also serves as Director of the NIDDK-supported Mid-Atlantic Nutrition Obesity Research Center and Director of the NIDDK-supported T32 Institutional Training Program in Diabetes.  His current research relates to genetics of metabolic disease and the pharmacogenetics of anti-diabetic drugs.


Dr. Taylor was employed by Bristol-Myers Squibb during 2002–2013 where, as vice president of cardiovascular and metabolic disease research, he participated in research and development leading to the approval of dapagliflozin, which is currently marketed by AstraZeneca. He has also served as a consultant for Aegerion Pharmaceuticals, Isis Pharmaceuticals, and Calibrium, LLC.